drugset

drugset / Trial / NCT04153279

CMV-TCR-T Cells for CM Virus Infection After HSCT

NCT04153279 ↗

Phase 1 Completed 17 enrolled Hebei Yanda Ludaopei Hospital China Immunotech (Beijing) Biotechnology Co., Ltd. · collab

NaSingle-groupOpen-labelTreatment

Summary

This is a single cente, single arm, open-label, phase I study to evaluate the safety and effectiveness of CMV-TCR-T cell immunotherapy in treating CMV virus infection after HSCT.

Timeline

Start: 2019-12-19
Primary completion: 2022-11-15
Completion: 2022-11-15

Publications

Liu G, Chen H, Cao X, Jia L, Rui W, Zheng H, Huang D, Liu F, Liu Y, Zhao X, Lu P, Lin X. Efficacy of pp65-specific TCR-T cell therapy in treating cytomegalovirus infection after hematopoietic stem cell transplantation. Am J Hematol. 2022 Nov;97(11):1453-1463. doi: 10.1002/ajh.26708. Epub 2022 Sep 22.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	CMV-TCR-T cells	Cell therapy	100000 cells/kg	Intravenous
Subject	CMV-TCR-T cells	Cell therapy	1e+06 cells/kg	Intravenous

Indications